AMO Pharma LTD Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AMO Pharma LTD's estimated annual revenue is currently $2M per year.(i)
  • AMO Pharma LTD's estimated revenue per employee is $155,000

Employee Data

  • AMO Pharma LTD has 13 Employees.(i)
  • AMO Pharma LTD grew their employee count by 8% last year.

AMO Pharma LTD's People

NameTitleEmail/Phone
1
VP, Head Chemistry, Manufacturing & ControlsReveal Email/Phone
2
ConsultantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M72-13%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$0.6M4-33%N/AN/A
#8
$4.8M31-6%N/AN/A
#9
$6.4M413%N/AN/A
#10
$4.2M27-18%N/AN/A
Add Company

What Is AMO Pharma LTD?

AMO Pharma is a biopharmaceutical company incorporated in February of 2015. The co-founder, Dr. Michael Snape, has extensive experience in senior scientific and operational roles in both large pharma and biotech companies spanning more than twenty-five years, and has brought together a targeted and experienced senior management team with a proven track record of success in all phases of product development and acquisition. The company is working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options. AMO-02 is an investigational medicine that has not yet been approved for the treatment of patients anywhere in the world. For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/.

keywords:N/A

N/A

Total Funding

13

Number of Employees

$2M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AMO Pharma LTD News

2022-04-13 - Fragile X Syndrome Market Outlook: Post Covid-19 Scenario by ... Blackswan Real Estate –

Fragile X Syndrome Market Outlook: Post Covid-19 Scenario by ... Blackswan Real Estate –

2022-04-13 - Glycogen Synthase Kinase 3 Beta Market Recovery and Impact ... Blackswan Real Estate –

Glycogen Synthase Kinase 3 Beta Market Recovery and Impact ... Blackswan Real Estate –

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M130%N/A
#2
$0.5M13-32%N/A
#3
N/A14-44%N/A
#4
$1.2M1417%N/A
#5
N/A14-26%N/A